Amylin: The Next Peptide Hormone Target for Obesity Drugs After GLP-1 | Research

The takeaway

Amylin receptor agonists are emerging as the next wave of peptide-based obesity drugs, with combination therapies (amylin + GLP-1) showing superior weight loss to monotherapy and potentially fewer GI side effects than GLP-1 drugs alone.

Combination > monotherapy
Amylin analog combined with other anti-obesity peptide drugs produced greater weight loss than either alone, and amylin drugs may cause fewer GI side effects than GLP-1 agonists

What the researchers found

The review identifies several key developments in amylin receptor agonist research:

• Amylin receptors are heterodimers of the calcitonin receptor and receptor activity-modifying proteins (RAMPs) — a unique and druggable receptor architecture

• Multiple amylin analogs are in preclinical and clinical development for obesity

• Combination therapy (amylin analog + other anti-obesity peptide drugs) has demonstrated higher clinical efficacy in reducing body weight than monotherapy

• Combination therapy is likely to be the first clinical application where an amylin analog is used for obesity

• Amylin receptor activators may have a more favorable adverse effect profile than GLP-1 receptor agonists

• Key engineering advances: mutations enhancing receptor affinity/potency, lipidation for long-acting properties, and methods for measuring selective amylin receptor activation

Why it matters

GLP-1 drugs dominate the obesity market, but their GI side effects limit tolerability for many patients. Amylin agonists represent a genuinely different peptide mechanism — working through the calcitonin receptor/RAMP system rather than the GLP-1 receptor. If amylin drugs prove more tolerable, they could become preferred options or powerful combination partners. The finding that amylin + GLP-1 beats either alone suggests the future of obesity pharmacotherapy may involve multi-peptide cocktails.

How the study worked

Narrative review collecting recent research publications and drug development information on amylin receptor activators. Covers preclinical studies, clinical trials, receptor pharmacology, peptide engineering approaches, and combination therapy data.

What this study cannot tell us

Narrative review without systematic methodology. Most amylin analog clinical data are from ongoing or recently completed trials with limited published details. The claim of fewer GI side effects versus GLP-1 drugs needs confirmation in head-to-head trials. Long-term safety data for amylin analogs in obesity are not available. The complexity of amylin receptor pharmacology (multiple RAMP subtypes) may complicate drug development.

How to read the evidence

This is a narrative review of the amylin receptor agonist field, covering preclinical through clinical-stage development. While it provides a comprehensive overview, the evidence for most claims is from early-stage clinical trials and preclinical data. The comparative advantage over GLP-1 drugs requires head-to-head clinical confirmation.

When this study was published

Published in 2025, this review captures the amylin drug pipeline at a pivotal moment as several candidates advance through clinical trials. The field is moving rapidly and new data may emerge soon.

The bigger picture

The obesity drug revolution started with GLP-1 agonists, expanded to dual GIP/GLP-1 agonists (tirzepatide), and is now reaching triple agonists and amylin analogs. Amylin represents a parallel peptide pathway that complements rather than duplicates GLP-1 signaling. The trend toward multi-target peptide combinations — hitting GLP-1, GIP, glucagon, and now amylin receptors — reflects a growing understanding that obesity is driven by multiple redundant appetite pathways, and no single target may be sufficient for maximal weight loss.

Questions still open

Will amylin-GLP-1 combination therapy become a standard treatment for obesity, and what are the optimal doses?
Can amylin analogs achieve meaningful weight loss as monotherapy, or will they only be used in combinations?
Which RAMP subtype-selective amylin agonists would be most effective for appetite suppression with fewest side effects?

Common questions

What is amylin and how is it different from GLP-1?

Amylin is a 37-amino acid peptide hormone released from the same pancreatic cells that produce insulin, but it works through a completely different receptor system — the calcitonin receptor paired with accessory proteins called RAMPs. Like GLP-1, amylin suppresses appetite and helps control blood sugar, but through different brain pathways. This makes amylin and GLP-1 drugs complementary — they can be combined for greater weight loss than either alone.

Could amylin drugs replace GLP-1 drugs for weight loss?

They're more likely to complement them than replace them. The most exciting finding is that combining amylin with GLP-1 drugs produces better weight loss than either alone. This combination approach is expected to be the first clinical use of amylin analogs for obesity. Amylin drugs may also have fewer stomach side effects than GLP-1 drugs, making them attractive for patients who can't tolerate GLP-1 therapy on its own.

Read the original research

A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy.

Current drug targets, 26(14), 980-991

View on PubMed ↗Publisher’s paper ↗

Citation

Lee, Sangmin. (2025). A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy.. Current drug targets, 26(14), 980-991. https://doi.org/10.2174/0113894501398624250819070004